Vertex Pharmaceuticals | VRTX

Stock Price
548.05
Daily Change
7.79 1.44%
Monthly
15.97%
Yearly
38.70%
Q3 Forecast
536.32

EPS Reference Time Actual Consensus Previous
2026-11-09 FY2026Q3 PM 4.88 4.80
2026-08-03 FY2026Q2 PM 4.73 4.72 4.52
2026-05-04 FY2026Q1 PM 4.47 4.43 4.06
2026-02-12 FY2025Q4 PM 5.03 5.12 3.98
2025-11-03 FY2025Q3 PM 4.80 4.62 4.38



Peers Price Chg Day Year Date
AbbVie 264.96 3.13 1.20% 25.81% Aug/21
Acadia Pharmaceuticals 29.50 0.46 1.58% 14.61% Aug/21
Agios Pharmaceuticals 33.09 -0.54 -1.61% -14.72% Aug/21
Alnylam Pharmaceuticals 236.22 6.92 3.02% -48.01% Aug/21
Amgen 439.33 5.60 1.29% 49.57% Aug/21
Arrowhead Research 87.11 -0.36 -0.41% 308.39% Aug/21
Biogen 216.78 2.43 1.13% 55.61% Aug/21
BioMarin Pharmaceutical 66.70 -0.98 -1.45% 13.86% Aug/21
Bristol-Myers Squibb 67.01 1.54 2.35% 39.84% Aug/21
Gilead Sciences 146.12 2.68 1.87% 27.32% Aug/21

Indexes Price Day Year Date
US500 7674 33.21 0.43% 18.67% Aug/21
USND 26180 128.98 0.49% 21.79% Aug/21
US400 3830 19.51 0.51% 17.64% Aug/21
US100 29309 95.70 0.33% 24.73% Aug/21

Vertex Pharmaceuticals traded at $548.05 this Friday August 21st, increasing $7.79 or 1.44 percent since the previous trading session. Looking back, over the last four weeks, Vertex Pharmaceuticals gained 15.97 percent. Over the last 12 months, its price rose by 38.70 percent. Looking ahead, we forecast Vertex Pharmaceuticals to be priced at 536.32 by the end of this quarter and at 502.62 in one year, according to Trading Economics global macro models projections and analysts expectations.

Vertex Pharmaceuticals Incorporated is a biotechnology company. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO. It offers its products to treat people with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. Its CFTR correctors, such as lumacaftor, tezacaftor, and elexacaftor, help CFTR proteins reach the cell surface. It offers pipeline of small molecule medicines in other serious diseases where it has insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases.



News Stream
Vertex Pharmaceuticals Stock Price Hits 4-week Low
Vertex Pharmaceuticals shares decreased to 465.80 USD, the lowest since June 2026. Over the past 4 weeks, Vertex Pharmaceuticals lost 0.33%, and in the last 12 months, it decreased 2.11%.
2026-07-23
Vertex Pharmaceuticals Stock Price Hits 15-month High
Vertex Pharmaceuticals shares increased to 513.25 USD, the highest since March 2025. Over the past 4 weeks, Vertex Pharmaceuticals gained 20.18%, and in the last 12 months, it increased 11.78%.
2026-07-02
Vertex Pharmaceuticals Stock Price Hits 16-week High
Vertex Pharmaceuticals shares increased to 504.12 USD, the highest since March 2026. Over the past 4 weeks, Vertex Pharmaceuticals gained 18.52%, and in the last 12 months, it increased 10.23%.
2026-07-02